Staphylococcus Aureus Bacteremia Clinical Trial
Official title:
A Prospective International Study of Staphylococcus Aureus Bacteraemia in Adults by the International Staphylococcus Aureus Collaboration
The purpose of this evaluation is to record the management and outcome of adults with S.aureus bacteraemia (SAB) across multiple European, Asian and North American sites and to identify key quality indicators associated with improved outcome.
Staphylococcus aureus (S. aureus) is one of the most common causes of bloodstream
infections. Associated mortality has been reported to vary widely (4%-40%) although no
obvious explanation for such variation has been identified.
Despite the existence of clinical guidelines, there is considerable variation in the
management of S.aureus bacteraemia (SAB) between centres. Part of the variation in clinical
management is due to the limited evidence base defining optimal therapy. Fewer than 1500
patients have been recruited to randomised controlled trials in the past 40 years; practice
is therefore based largely on experience and observational studies.
The purpose of this evaluation is to record the management and outcome of adults with SAB
across multiple European, Asian and North American sites. We aim to establish a broader
knowledge base, identify key quality indicators associated with improved outcomes, and to
provide comparator data to ensure that patients enrolled in randomized controlled trials are
representative of bacteraemic S. aureus patients as a whole. All participating centres are
experienced in the management of S. aureus bacteraemia and in conducting evaluations of
current management practice and outcomes from S. aureus bacteraemia. Data is checked for
plausibility by a centralized data quality control group.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05862025 -
Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).
|
N/A | |
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Recruiting |
NCT00622882 -
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
|
N/A | |
Recruiting |
NCT06168474 -
Evaluating Simplified Layered Consent for Clinical Trials
|
N/A | |
Completed |
NCT03163446 -
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
|
Phase 2 | |
Not yet recruiting |
NCT06336824 -
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
|
Phase 3 | |
Completed |
NCT02357966 -
A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus
|
Phase 1/Phase 2 | |
Recruiting |
NCT04886284 -
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
|
Phase 2 | |
Terminated |
NCT03089697 -
Phase IIa Clinical Study of N-Rephasin® SAL200
|
Phase 2 | |
Recruiting |
NCT03514446 -
Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia
|
Phase 4 | |
Withdrawn |
NCT03761953 -
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
|
Phase 4 | |
Recruiting |
NCT06249451 -
Staphylococcus Aureus Bacteraemia (SAB)-Support-Study
|
N/A | |
Completed |
NCT01701219 -
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
|
Phase 4 | |
Recruiting |
NCT05137119 -
Staphylococcus Aureus Network Adaptive Platform Trial
|
Phase 4 | |
Completed |
NCT03908086 -
Bloodstream Infections in Patients With Rheumatoid Arthritis
|
||
Terminated |
NCT04160468 -
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
|
Phase 3 | |
Completed |
NCT03138733 -
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
|
Phase 3 | |
Completed |
NCT02476487 -
The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia
|
N/A | |
Recruiting |
NCT05184764 -
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
|
Phase 1/Phase 2 | |
Completed |
NCT01971762 -
Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology
|
N/A |